The green tea polyphenolic catechin epigallocatechin gallate and neuroprotection

References

• Dulloo AG, Duret C, Rohrer D, Girardier L, Mensi N, Fathi M, et al. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. Am J Clin Nutr 1999;70(6):1040–5. [PubMed: 10584049].
   PubMed Web of Science ®Google Scholar
• Graham HN. Green tea composition, consumption, and polyphenol chemistry. Prev Med 1992;21(3):334–50. [PubMed: 1614995].
   PubMed Web of Science ®Google Scholar
• Sutherland BA, Rahman RM, Appleton I. Mechanisms of action of green tea catechins, with a focus on ischemia-induced neurodegeneration. J Nutr Biochem 2006;17(5):291–306. [PubMed: 16443357].
   PubMed Web of Science ®Google Scholar
• Zaveri NT. Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sci 2006;78(18):2073–80. [PubMed: 16445946].
   PubMed Web of Science ®Google Scholar
• Moore RJ, Jackson KG, Minihane AM. Green tea (Camellia sinensis) catechins and vascular function. Br J Nutr 2009;102(12):1790–802. [PubMed: 19751534].
   PubMed Web of Science ®Google Scholar
• Lee MJ, Maliakal P, Chen L, Meng X, Bondoc FY, Prabhu S, et al. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev 2002;11(10 Pt 1):1025–32 . [PubMed: 12376503].
   PubMed Web of Science ®Google Scholar
• Meng X, Sang S, Zhu N, Lu H, Sheng S, Lee MJ, et al. Identification and characterization of methylated and ring-fission metabolites of tea catechins formed in humans, mice, and rats. Chem Res Toxicol 2002;15(8):1042–50.
   PubMed Web of Science ®Google Scholar
• Williamson G, Dionisi F, Renouf M. Flavanols from green tea and phenolic acids from coffee: critical quantitative evaluation of the pharmacokinetic data in humans after consumption of single doses of beverages. Mol Nutr Food Res 2011;55(6):864–73.
   PubMed Web of Science ®Google Scholar
• Lin LC, Wang MN, Tseng TY, Sung JS, Tsai TH. Pharmacokinetics of (-)-epigallocatechin-3-gallate in conscious and freely moving rats and its brain regional distribution. J Agric Food Chem 2007;55(4):1517–24.
   PubMed Web of Science ®Google Scholar
• Pervin M, Unno K, Nakagawa A, Takahashi Y, Iguchi K, Yamamoto H, et al. Blood brain barrier permeability of (-)-epigallocatechin gallate, its proliferation-enhancing activity of human neuroblastoma SH-SY5Y cells, and its preventive effect on age-related cognitive dysfunction in mice. Biochem Biophys Rep 2017;9:180–6.
   PubMedGoogle Scholar
• Ritchie K, Lovestone S. The dementias. Lancet 2002;360(9347):1759–66.
   PubMed Web of Science ®Google Scholar
• Kuriyama S, Hozawa A, Ohmori K, Shimazu T, Matsui T, Ebihara S, et al. Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya project 1. Am J Clin Nutr 2006;83(2):355–61.
   PubMed Web of Science ®Google Scholar
• Ng TP, Feng L, Niti M, Kua EH, Yap KB. Tea consumption and cognitive impairment and decline in older Chinese adults. Am J Clin Nutr 2008;88(1):224–31.
   PubMed Web of Science ®Google Scholar
• Arab L, Biggs ML, O’Meara ES, Longstreth WT, Crane PK, Fitzpatrick AL. Gender differences in tea, coffee, and cognitive decline in the elderly: the cardiovascular health study. J Alzheimers Dis 2011;27(3):553–66.
   PubMed Web of Science ®Google Scholar
• Itoh T, Imano M, Nishida S, Tsubaki M, Hashimoto S, Ito A, et al. (-)-Epigallocatechin-3-gallate protects against neuronal cell death and improves cerebral function after traumatic brain injury in rats. Neuromolecular Med 2011;13(4):300–9.
   PubMed Web of Science ®Google Scholar
• Urdzikova L M, Ruzicka J, Karova K, Kloudova A, Svobodova B, Amin A, et al. A green tea polyphenol epigallocatechin-3-gallate enhances neuroregeneration after spinal cord injury by altering levels of inflammatory cytokines. Neuropharmacology 2017;126:213–23.
   PubMed Web of Science ®Google Scholar
• Xu Q, Langley M, Kanthasamy AG, Reddy MB. Epigallocatechin gallate has a neurorescue effect in a mouse model of Parkinson disease. J Nutr 2017;147(10):1926–31.
   PubMed Web of Science ®Google Scholar
• Chang X, Rong C, Chen Y, Yang C, Hu Q, Mo Y, et al. (-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer’s disease model mice by upregulating neprilysin expression. Exp Cell Res 2015;334(1):136–45.
   PubMed Web of Science ®Google Scholar
• Renno WM, Benov L, Khan KM. Possible role of antioxidative capacity of (-)-epigallocatechin-3-gallate treatment in morphological and neurobehavioral recovery after sciatic nerve crush injury. J Neurosurg Spine 2017;27(5):593–613.
   PubMed Web of Science ®Google Scholar
• Xifró X, Vidal-Sancho L, Boadas-Vaello P, Turrado C, Alberch J, Puig T, et al. Novel epigallocatechin-3-gallate (EGCG) derivative as a new therapeutic strategy for reducing neuropathic pain after chronic constriction nerve injury in mice. PLoS One 2015;10(4):e0123122.
   PubMed Web of Science ®Google Scholar
• Weinreb O, Amit T, Mandel S, Youdim MB. Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr 2009;4(4):283–96.
   PubMed Web of Science ®Google Scholar
• Ohishi T, Goto S, Monira P, Isemura M, Nakamura Y. Anti-inflammatory action of green tea. Antiinflamm Antiallergy Agents Med Chem 2016;15(2):74–90.
   PubMedGoogle Scholar
• Oliveira MR, Nabavi SF, Daglia M, Rastrelli L, Nabavi SM. Epigallocatechin gallate and mitochondria – a story of life and death. Pharmacol Res 2016;104:70–85.
   PubMed Web of Science ®Google Scholar
• Salah N, Miller NJ, Paganga G, Tijburg L, Bolwell GP, Rice-Evans C. Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch Biochem Biophys 1995;322(2):339–46.
   PubMed Web of Science ®Google Scholar
• Lawrence T, Fong C. The resolution of inflammation: anti-inflammatory roles for NF-kappaB. Int J Biochem Cell Biol 2010;42(4):519–23.
   PubMed Web of Science ®Google Scholar
• Mandel S, Maor G, Youdim MB. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. J Mol Neurosci 2004;24(3):401–16.
   PubMed Web of Science ®Google Scholar
• Kalfon L, Youdim MB, Mandel SA. Green tea polyphenol (-)-epigallocatechin-3-gallate promotes the rapid protein kinase C- and proteasome-mediated degradation of bad: implications for neuroprotection. J Neurochem 2007;100(4):992–1002.
   PubMed Web of Science ®Google Scholar
• Amar AP, Levy ML. Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury. Neurosurgery 1999;44(5):1027–39.
   PubMed Web of Science ®Google Scholar
• Hall ED. Lipid antioxidants in acute central nervous system injury. Ann Emerg Med 1993;22(6):1022–7.
   PubMed Web of Science ®Google Scholar
• Popovich PG, Wei P, Stokes BT. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J Comp Neurol 1997;377(3):443–64.
   PubMed Web of Science ®Google Scholar
• Liu XZ, Xu XM, Hu R, Du C, Zhang SX, McDonald JW, et al. Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci 1997;17(14):5395–406.
   PubMed Web of Science ®Google Scholar
• Khalatbary AR. Natural polyphenols and spinal cord injury. Iran Biomed J 2014;18(3):120–9.
   PubMedGoogle Scholar
• Khalatbary AR, Tiraihi T, Boroujeni MB, Ahmadvand H, Tavafi M, Tamjidipoor A. Effects of epigallocatechin gallate on tissue protection and functional recovery after contusive spinal cord injury in rats. Brain Res 2010;1306:168–75.
   PubMed Web of Science ®Google Scholar
• Khalatbary AR, Ahmadvand H. Effects of epigallocatechin gallate on tissue lipid peroxide levels in traumatized spinal cord of Rat. Iran J Basic Med Sci 2010;13(4):139–42.
   Web of Science ®Google Scholar
• Kwon BK, Tetzlaff W, Grauer JN, Beiner J, Vaccaro AR. Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J 2004;4(4):451–64.
   PubMedGoogle Scholar
• Khalatbary AR, Ahmadvand H. Anti-inflammatory effect of the epigallocatechin gallate following spinal cord trauma in rat. Iran Biomed J 2011;15(1–2):31–7.
   PubMedGoogle Scholar
• Ge R, Zhu Y, Diao Y, Tao L, Yuan W, Xiong XC. Anti-edema effect of epigallocatechin gallate on spinal cord injury in rats. Brain Res 2013;1527:40–6.
   PubMed Web of Science ®Google Scholar
• Nesic O, Lee J, Ye Z, Unabia GC, Rafati D, Hulsebosch CE, et al. Acute and chronic changes in aquaporin 4 expression after spinal cord injury. Neuroscience 2006;143(3):779–92.
   PubMed Web of Science ®Google Scholar
• Renno WM, Al-Khaledi G, Mousa A, Karam SM, Abul H, Asfar S. (-)-Epigallocatechin-3-gallate (EGCG) modulates neurological function when intravenously infused in acute and, chronically injured spinal cord of adult rats. Neuropharmacology 2014;77:100–19.
   PubMed Web of Science ®Google Scholar
• Tian W, Han XG, Liu YJ, Tang GQ, Liu B, Wang YQ, et al. Intrathecal epigallocatechin gallate treatment improves functional recovery after spinal cord injury by upregulating the expression of BDNF and GDNF. Neurochem Res 2013;38(4):772–9.
   PubMed Web of Science ®Google Scholar
• Burke D, Fullen BM, Stokes D, Lennon O. Neuropathic pain prevalence following spinal cord injury: a systematic review and meta-analysis. Eur J Pain 2017;21(1):29–44.
   PubMed Web of Science ®Google Scholar
• Álvarez-Pérez B, Homs J, Bosch-Mola M, Puig T, Reina F, Verdú E, et al. Epigallocatechin-3-gallate treatment reduces thermal hyperalgesia after spinal cord injury by down-regulating RhoA expression in mice. Eur J Pain 2016;20(3):341–52.
   PubMed Web of Science ®Google Scholar
• Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 2011;82(12):1807–21.
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Long DM. The molecular basis of brain injury and brain edema: the role of oxygen free radicals. Neurosurgery 1990;27(1):1–11.
   PubMed Web of Science ®Google Scholar
• Siesjö BK. Basic mechanisms of traumatic brain damage. Ann Emerg Med 1993;22(6):959–69.
   PubMed Web of Science ®Google Scholar
• Khoshnam SE, Winlow W, Farzaneh M, Farbood Y, Moghaddam HF. Pathogenic mechanisms following ischemic stroke. Neurol Sci 2017;38(7):1167–86.
   PubMed Web of Science ®Google Scholar
• Lee S, Suh S, Kim S. Protective effects of the green tea polyphenol (-)-epigallocatechin gallate against hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci Lett 2000;287(3):191–4.
   PubMed Web of Science ®Google Scholar
• Nagai K, Jiang MH, Hada J, Nagata T, Yajima Y, Yamamoto S, et al. (-)-Epigallocatechin gallate protects against NO stress-induced neuronal damage after ischemia by acting as an anti-oxidant. Brain Res 2002;956(2):319–22.
   PubMed Web of Science ®Google Scholar
• Choi YB, Kim YI, Lee KS, Kim BS, Kim DJ. Protective effect of epigallocatechin gallate on brain damage after transient middle cerebral artery occlusion in rats. Brain Res 2004;1019(1–2):47–54.
   PubMed Web of Science ®Google Scholar
• Park JW, Hong JS, Lee KS, Kim HY, Lee JJ, Lee SR. Green tea polyphenol (-)-epigallocatechin gallate reduces matrix metalloproteinase-9 activity following transient focal cerebral ischemia. J Nutr Biochem 2010;21(11):1038–44.
   PubMed Web of Science ®Google Scholar
• Han J, Wang M, Jing X, Shi H, Ren M, Lou H. (-)-Epigallocatechin gallate protects against cerebral ischemia-induced oxidative stress via Nrf2/ARE signaling. Neurochem Res 2014;39(7):1292–9.
   PubMed Web of Science ®Google Scholar
• Alfieri A, Srivastava S, Siow RC, Modo M, Fraser PA, Mann GE. Targeting the Nrf2-Keap1 antioxidant defence pathway for neurovascular protection in stroke. J Physiol 2011;589(17):4125–36.
   PubMed Web of Science ®Google Scholar
• Bai Q, Lyu Z, Yang X, Pan Z, Lou J, Dong T. Epigallocatechin-3-gallate promotes angiogenesis via up-regulation of Nfr2 signaling pathway in a mouse model of ischemic stroke. Behav Brain Res 2017;321:79–86.
   PubMed Web of Science ®Google Scholar
• Zhang F, Li N, Jiang L, Chen L, Huang M. Neuroprotective effects of (-)-epigallocatechin-3-gallate against focal cerebral ischemia/reperfusion injury in rats through attenuation of inflammation. Neurochem Res 2015;40(8):1691–8.
   PubMed Web of Science ®Google Scholar
• Wu KJ, Hsieh MT, Wu CR, Wood WG, Chen YF. Green Tea extract ameliorates learning and memory deficits in ischemic rats via its active component polyphenol epigallocatechin-3-gallate by modulation of oxidative stress and neuroinflammation. Evid Based Complement Alternat Med 2012;2012:1–11.
   Google Scholar
• Lee H, Bae JH, Lee SR. Protective effect of green tea polyphenol EGCG against neuronal damage and brain edema after unilateral cerebral ischemia in gerbils. J Neurosci Res 2004;77(6):892–900.
   PubMed Web of Science ®Google Scholar
• Sutherland BA, Shaw OM, Clarkson AN, Jackson DN, Sammut IA, Appleton I. Neuroprotective effects of (-)-epigallocatechin gallate following hypoxia-ischemia-induced brain damage: novel mechanisms of action. FASEB J 2005;19(2):258–60.
   PubMedGoogle Scholar
• Park JW, Jang YH, Kim JM, Lee H, Park WK, Lim MB, et al. Green tea polyphenol (-)-epigallocatechin gallate reduces neuronal cell damage and up-regulation of MMP-9 activity in hippocampal CA1 and CA2 areas following transient global cerebral ischemia. J Neurosci Res 2009;87(2):567–75.
   PubMed Web of Science ®Google Scholar
• Itoh T, Tabuchi M, Mizuguchi N, Imano M, Tsubaki M, Nishida S, et al. Neuroprotective effect of (-)-epigallocatechin-3-gallate in rats when administered pre- or post-traumatic brain injury. J Neural Transm (Vienna) 2013;120(5):767–83.
   PubMed Web of Science ®Google Scholar
• Itoh T, Imano M, Nishida S, Tsubaki M, Mizuguchi N, Hashimoto S, et al. (-)-Epigallocatechin-3-gallate increases the number of neural stem cells around the damaged area after rat traumatic brain injury. J Neural Transm (Vienna) 2012;119(8):877–90.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wang B, Cao S, Wang Y. Epigallocatechin-3-Gallate (EGCG) attenuates traumatic brain injury by inhibition of edema formation and oxidative stress. Korean J Physiol Pharmacol 2015;19(6):491–7.
   PubMed Web of Science ®Google Scholar
• Laferrière A, Millecamps M, Xanthos DN, Xiao WH, Siau C, de Mos M, et al. Cutaneous tactile allodynia associated with microvascular dysfunction in muscle. Mol Pain 2008;4:49.
   PubMed Web of Science ®Google Scholar
• Lundborg G, Rosén B. Hand function after nerve repair. Acta Physiol 2007;189(2):207–17.
   PubMed Web of Science ®Google Scholar
• Choi DW. Excitotoxic cell death. J Neurobiol 1992;23(9):1261–76.
   PubMedGoogle Scholar
• Liu Z, Martin LJ. Motor neurons rapidly accumulate DNA single-strand breaks after in vitro exposure to nitric oxide and peroxynitrite and in vivo axotomy. J Comp Neurol 2001;432(1):35–60.
   PubMed Web of Science ®Google Scholar
• Li HY, Ruan YW, Ren CR, Cui Q, So KF. Mechanisms of secondary degeneration after partial optic nerve transaction. Neural Regen Res 2014;9(6):565–74.
   PubMed Web of Science ®Google Scholar
• Peng PH, Chiou LF, Chao HM, Lin S, Chen CF, Liu JH, et al. Effects of epigallocatechin-3-gallate on rat retinal ganglion cells after optic nerve axotomy. Exp Eye Res 2010;90(4):528–34.
   PubMed Web of Science ®Google Scholar
• Xie J, Jiang L, Zhang T, Jin Y, Yang D, Chen F. Neuroprotective effects of epigallocatechin-3-gallate (EGCG) in optic nerve crush model in rats. Neurosci Lett 2010;479(1):26–30.
   PubMed Web of Science ®Google Scholar
• Wei IH, Tu HC, Huang CC, Tsai MH, Tseng CY, Shieh JY. (-)-Epigallocatechin gallate attenuates NADPH-d/nNOS expression in motor neurons of rats following peripheral nerve injury. BMC Neurosci 2011;12:52.
   PubMed Web of Science ®Google Scholar
• Kuang X, Huang Y, Gu HF, Zu XY, Zou WY, Song ZB, Guo QL. Effects of intrathecal epigallocatechin gallate, an inhibitor of toll-like receptor 4, on chronic neuropathic pain in rats. Eur J Pharmacol 2012;676(1–3):51–6.
   PubMed Web of Science ®Google Scholar
• Bosch-Mola M, Homs J, Álvarez-Pérez B, Puig T, Reina F, Verdú E, et al. (-)-Epigallocatechin-3-Gallate antihyperalgesic effect associates With reduced CX3CL1 chemokine expression in spinal cord. Phytother Res 2017;31(2):340–4.
   PubMed Web of Science ®Google Scholar
• Renno WM, Al-Maghrebi M, Alshammari A, George P. (-)-Epigallocatechin-3-gallate (EGCG) attenuates peripheral nerve degeneration in rat sciatic nerve crush injury. Neurochem Int 2013;62(3):221–31.
   PubMed Web of Science ®Google Scholar
• Renno WM, Al-Maghrebi M, Rao MS, Khraishah H. (-)-Epigallocatechin-3-gallate modulates spinal cord neuronal degeneration by enhancing growth-associated protein 43. B-cell Lymphoma; 2, and decreasing B-cell lymphoma 2-associated x protein expression after sciatic nerve crush injury. J Neurotrauma 2015;32(3):170–84.
   PubMed Web of Science ®Google Scholar
• Yildirim AE, Dalgic A, Divanlioglu D, Akdag R, Cetinalp NE, Alagoz F, et al. Biochemical and histopathological effects of catechin on experimental peripheral nerve injuries. Turk Neurosurg 2015;25(3):453–60.
   PubMed Web of Science ®Google Scholar
• Renno WM, Khan KM, Benov L. Is there a role for neurotrophic factors and their receptors in augmenting the neuroprotective effect of (-)-epigallocatechin-3-gallate treatment of sciatic nerve crush injury? Neuropharmacology 2016;102:1–20.
   PubMed Web of Science ®Google Scholar
• Kian K, Khalatbary AR, Ahmadvand H, Karimpour Malekshah A, Shams Z. Neuroprotective effects of (-)-epigallocatechin-3-gallate (EGCG) against peripheral nerve transection-induced apoptosis. Nutr Neurosci 2018:1–9 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Choonara YE, Pillay V, du Toit LC, Modi G, Naidoo D, Ndesendo VM, et al. Trends in the Molecular Pathogenesis and Clinical Therapeutics of Common Neurodegenerative Disorders. Int J Mol Sci 2009;10(6):2510–57.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L. Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications. Oxid Med Cell Longev 2017;2017:1–11.
   Web of Science ®Google Scholar
• Albers DS, Beal MF. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J Neural Transm Suppl 2000;59:133–54.
   PubMedGoogle Scholar
• Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease – a double-edged sword. Neuron 2002;35(3):419–32.
   PubMed Web of Science ®Google Scholar
• Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, et al. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 2005;25(38):8807–14.
   PubMed Web of Science ®Google Scholar
• Kumar A, Singh A, Ekavali E. A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep 2015;67(2):195–203.
   PubMed Web of Science ®Google Scholar
• Ferreiro E, Oliveira CR, Pereira CM. The release of calcium from the endoplasmic reticulum induced by amyloid-beta and prion peptides activates the mitochondrial apoptotic pathway. Neurobiol Dis 2008;30(3):331–42.
   PubMed Web of Science ®Google Scholar
• He M, Liu MY, Wang S, Tang QS, Yao WF, Zhao HS, et al. Research on EGCG improving the degenerative changes of the brain in AD model mice induced with chemical drugs. Zhong Yao Cai 2012;35(10):1641–4.
   PubMedGoogle Scholar
• Zhang X, Wu M, Lu F, Luo N, He ZP, Yang H. Involvement of α7 nAChR signaling cascade in epigallocatechin gallate suppression of β-amyloid-induced apoptotic cortical neuronal insults. Mol Neurobiol 2014;49(1):66–77.
   PubMed Web of Science ®Google Scholar
• Kumar V, Gupta AK, Shukla RK, Tripathi VK, Jahan S, Pandey A, et al. Molecular mechanism of switching of TrkA/p75(NTR) signaling in monocrotophos induced neurotoxicity. Sci Rep 2015;5:14038.
   PubMed Web of Science ®Google Scholar
• Liu M, Chen F, Sha L, Wang S, Tao L, Yao L, et al. (-)-Epigallocatechin-3-gallate ameliorates learning and memory deficits by adjusting the balance of TrkA/p75NTR signaling in APP/PS1 transgenic mice. Mol Neurobiol 2014;49(3):1350–63.
   PubMed Web of Science ®Google Scholar
• Walker JM, Klakotskaia D, Ajit D, Weisman GA, Wood WG, Sun GY, et al. Beneficial effects of dietary EGCG and voluntary exercise on behavior in an Alzheimer’s disease mouse model. J Alzheimers Dis 2015;44(2):561–72.
   PubMed Web of Science ®Google Scholar
• Guo Y, Zhao Y, Nan Y, Wang X, Chen Y, Wang S. (-)-Epigallocatechin-3-gallate ameliorates memory impairment and rescues the abnormal synaptic protein levels in the frontal cortex and hippocampus in a mouse model of Alzheimer’s disease. Neuroreport 2017;28(10):590–7.
   PubMed Web of Science ®Google Scholar
• Guéroux M, Fleau C, Slozeck M, Laguerre M, Pianet I. Epigallocatechin 3-gallate as an inhibitor of Tau phosphorylation and aggregation: a molecular and structural insight. J Prev Alzheimers Dis 2017;4(4):218–25.
   PubMed Web of Science ®Google Scholar
• Alexander GE. Biology of Parkinson’s disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialog Clin Neurosci 2004;6(3):259–80.
   PubMedGoogle Scholar
• Abushouk AI, Negida A, Ahmed H, Abdel-Daim MM. Neuroprotective mechanisms of plant extracts against MPTP induced neurotoxicity: future applications in Parkinson’s disease. Biomed Pharmacother 2017;85:635–45.
   PubMed Web of Science ®Google Scholar
• Li R, Huang YG, Fang D, Le WD. (-)-Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury. J Neurosci Res 2004;78(5):723–31.
   PubMed Web of Science ®Google Scholar
• Reddy PH, Shirendeb UP. Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington’s disease. Biochim Biophys Acta 2012;1822(2):101–10.
   PubMed Web of Science ®Google Scholar
• Kumar P, Kumar A. Effect of lycopene and epigallocatechin-3-gallate against 3-nitropropionic acid induced cognitive dysfunction and glutathione depletion in rat: a novel nitric oxide mechanism. Food Chem Toxicol 2009;47(10):2522–30.
   PubMed Web of Science ®Google Scholar
• Kumar P, Kumar A. Protective effects of epigallocatechin gallate following 3-nitropropionic acid-induced brain damage: possible nitric oxide mechanisms. Psychopharmacology 2009;207(2):257–70.
   PubMed Web of Science ®Google Scholar
• Lin SM, Wang SW, Ho SC, Tang YL. Protective effect of green tea (-)-epigallocatechin-3-gallate against the monoamine oxidase B enzyme activity increase in adult rat brains. Nutrition 2010;26(11–12):1195–200.
   PubMed Web of Science ®Google Scholar
• Herges K, Millward JM, Hentschel N, Infante-Duarte C, Aktas O, Zipp F. Neuroprotective effect of combination therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation. PLoS One 2011;6(10):e25456.
   PubMed Web of Science ®Google Scholar
• Ferreira N, Saraiva MJ, Almeida MR. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: ‘in vivo’ evidence from FAP mice models. PLoS One 2012;7(1):e29933.
   PubMed Web of Science ®Google Scholar
• He Y, Tan D, Mi Y, Zhou Q, Ji S. Epigallocatechin-3-gallate attenuates cerebral cortex damage and promotes brain regeneration in acrylamide-treated rats. Food Funct 2017;8(6):2275–82.
   PubMed Web of Science ®Google Scholar
• Esmaeelpanah E, Razavi BM, Vahdati Hasani F, Hosseinzadeh H. Evaluation of epigallocatechin gallate and epicatechin gallate effects on acrylamide-induced neurotoxicity in rats and cytotoxicity in PC 12 cells. Drug Chem Toxicol 2017:1–8 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• He Y, Tan D, Bai B, Wu Z, Ji S. Epigallocatechin-3-gallate attenuates acrylamide-induced apoptosis and astrogliosis in rat cerebral cortex. Toxicol Mech Methods 2017;27(4):298–306.
   PubMed Web of Science ®Google Scholar
• Ding ML, Ma H, Man YG, Lv HY. Protective effects of a green tea polyphenol, epigallocatechin-3-gallate, against sevoflurane-induced neuronal apoptosis involve regulation of CREB/BDNF/TrkB and PI3 K/Akt/mTOR signalling pathways in neonatal mice. Can J Physiol Pharmacol 2017;95(12):1396–1405.
   PubMed Web of Science ®Google Scholar
• Nie G, Jin C, Cao Y, Shen S, Zhao B. Distinct effects of tea catechins on 6-hydroxydopamine-induced apoptosis in PC12 cells. Arch Biochem Biophys 2002;397(1):84–90.
   PubMed Web of Science ®Google Scholar
• Jung JY, Han CR, Jeong YJ, Kim HJ, Lim HS, Lee KH, et al. Epigallocatechin gallate inhibits nitric oxide-induced apoptosis in rat PC12 cells. Neurosci Lett 2007;411(3):222–7.
   PubMed Web of Science ®Google Scholar
• Koh SH, Kim SH, Kwon H, Park Y, Kim KS, Song CW, et al. Epigallocatechin gallate protects nerve growth factor differentiated PC12 cells from oxidative-radical-stress-induced apoptosis through its effect on phosphoinositide 3-kinase/Akt and glycogen synthase kinase-3. Brain Res Mol Brain Res 2003;118(1–2):72–81.
   PubMedGoogle Scholar
• Srividhya R, Kalaiselvi P. Neuroprotective potential of epigallo catechin-3-gallate in PC-12 cells. Neurochem Res 2013;38(3):486–93.
   PubMed Web of Science ®Google Scholar
• Jung JY, Mo HC, Yang KH, Jeong YJ, Yoo HG, Choi NK, et al. Inhibition by epigallocatechin gallate of CoCl2-induced apoptosis in rat PC12 cells. Life Sci 2007;80(15):1355–63.
   PubMed Web of Science ®Google Scholar
• Hou RR, Chen JZ, Chen H, Kang XG, Li MG, Wang BR. Neuroprotective effects of (-)-epigallocatechin-3-gallate (EGCG) on paraquat-induced apoptosis in PC12 cells. Cell Biol Int 2008;32(1):22–30.
   PubMed Web of Science ®Google Scholar
• Nie G, Cao Y, Zhao B. Protective effects of green tea polyphenols and their major component. epigallocatechin: 3), -gallate (EGCG), on 6-hydroxydopamine-induced apoptosis in PC12 cells. Redox Rep 2002;7(3):171–7.
   PubMed Web of Science ®Google Scholar
• Mandel S, Reznichenko L, Amit T, Youdim MB. Green tea polyphenol (-)-epigallocatechin-3-gallate protects rat PC12 cells from apoptosis induced by serum withdrawal independent of P13-Akt pathway. Neurotox Res 2003;5(6):419–24.
   PubMed Web of Science ®Google Scholar
• Jeong JH, Kim HJ, Lee TJ, Kim MK, Park ES, Choi BS. Epigallocatechin 3-gallate attenuates neuronal damage induced by 3-hydroxykynurenine. Toxicology 2004;195(1):53–60.
   PubMed Web of Science ®Google Scholar
• Tai KK, Truong DD. (-)-Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, reduces dichlorodiphenyl-trichloroethane (DDT)-induced cell death in dopaminergic SHSY-5Y cells. Neurosci Lett 2010;482(3):183–7.
   PubMed Web of Science ®Google Scholar
• Levites Y, Amit T, Youdim MB, Mandel S. Involvement of protein kinase C activation and cell survival/ cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action. J Biol Chem 2002;277(34):30574–80.
   PubMed Web of Science ®Google Scholar
• Avramovich-Tirosh Y, Reznichenko L, Mit T, Zheng H, Fridkin M, Weinreb O, et al. Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron-chelating-antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res 2007;4(4):403–11.
   PubMed Web of Science ®Google Scholar
• Zhang B, Rusciano D, Osborne NN. Orally administered epigallocatechin gallate attenuates retinal neuronal death in vivo and light-induced apoptosis in vitro. Brain Res 2008;1198:141–52.
   PubMed Web of Science ®Google Scholar
• Chan CM, Huang JH, Lin HH, Chiang HS, Chen BH, Hong JY, et al. Protective effects of (-)-epigallocatechin gallate on UVA-induced damage in ARPE19 cells. Mol Vis 2008;14:2528–34.
   PubMed Web of Science ®Google Scholar
• Jang S, Jeong HS, Park JS, Kim YS, Jin CY, Seol MB, et al. Neuroprotective effects of (-)-epigallocatechin-3-gallate against quinolinic acid-induced excitotoxicity via PI3 K pathway and NO inhibition. Brain Res 2010;1313:25–33.
   PubMed Web of Science ®Google Scholar
• He Q, Bao L, Zimering J, Zan K, Zhang Z, Shi H, et al. The protective role of (-)-epigallocatechin-3-gallate in thrombin-induced neuronal cell apoptosis and JNK-MAPK activation. Neuroreport 2015;26(7):416–23.
   PubMed Web of Science ®Google Scholar
• Cia D, Vergnaud-Gauduchon J, Jacquemot N, Doly M. Epigallocatechin gallate (EGCG) prevents H2O2-induced oxidative stress in primary rat retinal pigment epithelial cells. Curr Eye Res 2014;39(9):944–52.
   PubMed Web of Science ®Google Scholar
• Jin J, Ying H, Huang M, Du Q. Bioactive compounds in green tea leaves attenuate the injury of retinal ganglion RGC-5 cells induced by H2O2 and ultraviolet radiation. Pak J Pharm Sci 2015: 28(6. Suppl):2267–72.
   PubMed Web of Science ®Google Scholar
• Schroeder EK, Kelsey NA, Doyle J, Breed E, Bouchard RJ, Loucks FA, et al. Green tea epigallocatechin 3-gallate accumulates in mitochondria and displays a selective antiapoptotic effect against inducers of mitochondrial oxidative stress in neurons. Antioxid Redox Signal 2009;11(3):469–80.
   PubMed Web of Science ®Google Scholar
• Lee JH, Moon JH, Kim SW, Jeong JK, Nazim UM, Lee YJ, et al. EGCG-mediated autophagy flux has a neuroprotection effect via a class III histone deacetylase in primary neuron cells. Oncotarget 2015;6(12):9701–17.
   PubMedGoogle Scholar
• Du K, Liu M, Zhong X, Yao W, Xiao Q, Wen Q, et al. Epigallocatechin gallate reduces amyloid β-induced neurotoxicity via inhibiting endoplasmic reticulum stress-mediated apoptosis. Mol Nutr Food Res 2018;62(8):e1700890.
   PubMed Web of Science ®Google Scholar
• Choi YT, Jung CH, Lee SR, Bae JH, Baek WK, Suh MH, et al. The green tea polyphenol (-)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons. Life Sci 2001;70(5):603–14.
   PubMed Web of Science ®Google Scholar
• Reznichenko L, Amit T, Zheng H, Avramovich-Tirosh Y, Youdim MB, Weinreb O, et al. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer’s disease. J Neurochem 2006;97(2):527–36.
   PubMed Web of Science ®Google Scholar
• Lin CL, Chen TF, Chiu MJ, Way TD, Lin JK. Epigallocatechin gallate (EGCG) suppresses beta-amyloid-induced neurotoxicity through inhibiting c-Abl/FE65 nuclear translocation and GSK3 beta activation. Neurobiol Aging 2009;30(1):81–92.
   PubMed Web of Science ®Google Scholar
• Levites Y, Amit T, Mandel S, Youdim MB. Neuroprotection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3-gallate. FASEB J 2003;17(8):952–4.
   PubMedGoogle Scholar
• Lorenzen N, Nielsen SB, Yoshimura Y, Vad BS, Andersen CB, Betzer C, et al. How epigallocatechin gallate can inhibit α-synuclein oligomer toxicity in vitro. J Biol Chem 2014;289(31):21299–310.
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhang Y, Quan Z, Wong W, Guo J, Zhang R, et al. Epigallocatechin gallate (EGCG) inhibits alpha-synuclein aggregation: a potential agent for Parkinson’s disease. Neurochem Res 2016;41(10):2788–96.
   PubMed Web of Science ®Google Scholar
• Zhao J, Xu L, Liang Q, Sun Q, Chen C, Zhang Y, et al. Metal chelator EGCG attenuates Fe(III)-induced conformational transition of α-synuclein and protects AS-PC12 cells against Fe(III)-induced death. J Neurochem 2017;143(1):136–46.
   PubMed Web of Science ®Google Scholar
• Ehrnhoefer DE, Duennwald M, Markovic P, Wacker JL, Engemann S, Roark M, et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington’s disease models. Hum Mol Genet 2006;15(18):2743–51.
   PubMed Web of Science ®Google Scholar
• Bonanomi M, Visentin C, Natalello A, Spinelli M, Vanoni M, Airoldi C, et al. How epigallocatechin-3-gallate and tetracycline interact with the Josephin domain of ataxin-3 and alter its aggregation mode. Chemistry 2015;21(50):18383–93.
   PubMed Web of Science ®Google Scholar
• Bonanomi M, Natalello A, Visentin C, Pastori V, Penco A, Cornelli G, et al. Epigallocatechin-3-gallate and tetracycline differently affect ataxin-3 fibrillogenesis and reduce toxicity in spinocerebellar ataxia type 3 model. Hum Mol Genet 2014;23(24):6542–52.
   PubMed Web of Science ®Google Scholar
• Chesser AS, Ganeshan V, Yang J, Johnson GV. Epigallocatechin-3-gallate enhances clearance of phosphorylated tau in primary neurons. Nutr Neurosci 2016;19(1):21–31.
   PubMed Web of Science ®Google Scholar
• Li R, Peng N, Du F, Li XP, Le WD. Epigallocatechin Gallate Protects Dopaminergic Neurons Against: 1), -methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by inhibiting microglial cell activation. Nan Fang Yi Ke Da Xue Xue Bao 2006;26(4):376–80.
   PubMedGoogle Scholar
• Lee SJ, Lee KW. Protective effect of (-)-epigallocatechin gallate against advanced glycation end products-induced injury in neuronal cells. Biol Pharm Bull 2007;30(8):1369–73.
   PubMed Web of Science ®Google Scholar
• Ye Q, Ye L, Xu X, Huang B, Zhang X, Zhu Y, et al. Epigallocatechin-3-gallate suppresses 1-methyl-4-phenyl-pyridine-induced oxidative stress in PC12 cells via the SIRT1/PGC-1α signaling pathway. BMC Complement Altern Med 2012;12:82.
   PubMed Web of Science ®Google Scholar
• Moldzio R, Radad K, Krewenka C, Kranner B, Duvigneau JC, Wang Y, et al. Effects of epigallocatechin gallate on rotenone-injured murine brain cultures. J Neural Transm (Vienna) 2010;117(1):5–12.
   PubMed Web of Science ®Google Scholar
• Fu Y, Koo MW. EGCG protects HT-22 cells against glutamate-induced oxidative stress. Neurotox Res 2006;10(1):23–30.
   PubMed Web of Science ®Google Scholar
• Thichanpiang P, Wongprasert K. Green tea polyphenol epigallocatechin-3-gallate attenuates TNF-α-induced intercellular adhesion molecule-1 expression and monocyte adhesion to retinal pigment epithelial cells. Am J Chin Med 2015;43(1):103–19.
   PubMed Web of Science ®Google Scholar
• Shaban S, El-Husseny MWA, Abushouk AI, Salem AMA, Mamdouh M, Abdel-Daim MM. Effects of antioxidant supplements on the survival and differentiation of stem cells. Oxid Med Cell Longev 2017;2017:5032102.
   PubMedGoogle Scholar
• Gundimeda U, McNeill TH, Schiffman JE, Hinton DR, Gopalakrishna R. Green tea polyphenols potentiate the action of nerve growth factor to induce neuritogenesis: possible role of reactive oxygen species. J Neurosci Res 2010;88(16):3644–55.
   PubMed Web of Science ®Google Scholar
• Gundimeda U, McNeill TH, Fan TK, Deng R, Rayudu D, Chen Z, et al. Green tea catechins potentiate the neuritogenic action of brain-derived neurotrophic factor: role of 67-kDa laminin receptor and hydrogen peroxide. Biochem Biophys Res Commun 2014;445(1):218–24.
   PubMed Web of Science ®Google Scholar
• Wang Y, Li M, Xu X, Song M, Tao H, Bai Y. Green tea epigallocatechin-3-gallate (EGCG) promotes neural progenitor cell proliferation and sonic hedgehog pathway activation during adult hippocampal neurogenesis. Mol Nutr Food Res 2012;56(8):1292–303.
   PubMed Web of Science ®Google Scholar
• Ortiz-López L, Márquez-Valadez B, Gómez-Sánchez A, Silva-Lucero MD, Torres-Pérez M, Téllez-Ballesteros RI, et al. Green tea compound epigallo-catechin-3-gallate (EGCG) increases neuronal survival in adult hippocampal neurogenesis in vivo and in vitro. Neuroscience 2016;322:208–20.
   PubMed Web of Science ®Google Scholar
• Scholey A, Downey LA, Ciorciari J, Pipingas A, Nolidin K, Finn M, et al. Acute neurocognitive effects of epigallocatechin gallate (EGCG). Appetite 2012;58(2):767–70.
   PubMed Web of Science ®Google Scholar
• Mähler A, Steiniger J, Bock M, Klug L, Parreidt N, Lorenz M, et al. Metabolic response to epigallocatechin-3-gallate in relapsing-remitting multiple sclerosis: a randomized clinical trial. Am J Clin Nutr 2015;101(3):487–95.
   PubMed Web of Science ®Google Scholar
• Levin J, Maaß S, Schuberth M, Respondek G, Paul F, Mansmann U, et al. The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. J Neural Transm (Vienna) 2016;123(4):439–45.
   PubMed Web of Science ®Google Scholar
• Wightman EL, Haskell CF, Forster JS, Veasey RC, Kennedy DO. Epigallocatechin gallate, cerebral blood flow parameters, cognitive performance and mood in healthy humans: a double-blind, placebo-controlled, crossover investigation. Hum Psychopharmacol 2012;27(2):177–86.
   PubMed Web of Science ®Google Scholar
• Wang XH, You YP. Epigallocatechin gallate extends therapeutic window of recombinant tissue plasminogen activator treatment for brain ischemic stroke: a randomized double-blind and placebo-controlled trial. Clin Neuropharmacol 2017;40(1):24–28.
   PubMed Web of Science ®Google Scholar